Zespół pradera-williego
Epidemiologia

Zespół Pradera-Williego (ZPW) jest najczęstszą genetyczną przyczyną zagrażającej życiu otyłości, o częstości występowania od 1:10 000 do 1:30 000 urodzeń, z globalną populacją około 350 000-400 000 chorych. Diagnostyka opiera się na cechach klinicznych i analizie metylacji DNA, umożliwiającej rozpoznanie ponad 99% przypadków, z wiekiem diagnozy obniżonym do pierwszych miesięcy życia. Kompleksowy nadzór medyczny obejmuje regularne monitorowanie parametrów takich jak hemoglobina glikowana, TSH, wzrost, masa ciała, ocena zachowań obsesyjno-kompulsyjnych, badania okulistyczne i densytometrię kości. Roczna śmiertelność w ZPW wynosi 1-4%, z medianą wieku zgonu około 30 lat, a główną przyczyną zgonów są powikłania oddechowe, zwłaszcza niewydolność oddechowa i infekcje dróg oddechowych.

  1. Epidemiologia zespołu Pradera-Williego
    1. Zróżnicowanie geograficzne
    2. Różnice etniczne i rasowe
  2. Monitorowanie i nadzór nad zespołem Pradera-Williego
    1. Wczesna diagnoza i jej znaczenie
    2. Zalecany nadzór i monitorowanie
    3. Umieralność i czynniki ryzyka
  3. Systemy nadzoru i rejestry
    1. Istniejące rejestry i ich znaczenie
    2. Prognozy i trendy
  4. Wyzwania w nadzorze epidemiologicznym
    1. Problemy diagnostyczne
    2. Potrzeby badawcze
  5. Znaczenie multidyscyplinarnego podejścia
    1. Kolejne rozdziały

Epidemiologia zespołu Pradera-Williego

Zespół Pradera-Williego (ZPW) jest złożonym zaburzeniem genetycznym, uznawanym za najczęstszą genetyczną przyczynę zagrażającej życiu otyłości. Częstość występowania tego zespołu szacuje się na 1 przypadek na 10 000 do 30 000 urodzeń, przy czym dane te różnią się w zależności od badanej populacji i stosowanych metod diagnostycznych.1234

Na całym świecie zespół Pradera-Williego dotyka około 350 000-400 000 osób, z czego około 20 000 mieszka w Stanach Zjednoczonych.123 Występowanie zespołu jest równomierne u obu płci, nie wykazując preferencji płciowych.123

Zróżnicowanie geograficzne

Częstość występowania zespołu Pradera-Williego różni się geograficznie, choć nie ma silnych dowodów na zwiększone ryzyko w określonych krajach czy pulach genowych.1 Wśród danych epidemiologicznych z różnych regionów świata można zauważyć następujące różnice:

  • Stany Zjednoczone: 1:10 000 do 1:30 00012
  • Szwecja (obszary wiejskie): 1:8 00012
  • Zachodnia Japonia: 1:16 00012
  • Australia: 1:16 0001
  • Flandria: 1:76 5001
  • Wielka Brytania: około 1:45 00012

Najnowsze dane z badania populacyjnego przeprowadzonego w Stanach Zjednoczonych na podstawie analizy roszczeń medycznych wskazują na częstość występowania zdiagnozowanych przypadków ZPW na poziomie 2,7 na 100 000 osób (czyli 1 na 37 037), co przekłada się na około 8 870 pacjentów zdiagnozowanych w USA w 2018 roku.1

Różnice etniczne i rasowe

Zespół Pradera-Williego dotyka osoby wszystkich ras i grup etnicznych.1 Większość badań nie wykazała spójnych różnic w częstości występowania między grupami rasowymi.1 Jednakże niektóre źródła sugerują, że ZPW może być nieproporcjonalnie częściej raportowany wśród osób rasy kaukaskiej, choć może to wynikać z różnic w dostępie do diagnostyki i opieki zdrowotnej.1

Monitorowanie i nadzór nad zespołem Pradera-Williego

Ze względu na złożony charakter zespołu Pradera-Williego i jego wpływ na wiele układów organizmu, kluczowe znaczenie ma wdrożenie kompleksowego systemu nadzoru i monitorowania pacjentów. Wczesna diagnoza i interwencja mogą znacząco poprawić jakość życia, zapobiec powikłaniom i wydłużyć oczekiwaną długość życia pacjentów z ZPW.12

Wczesna diagnoza i jej znaczenie

Diagnoza zespołu Pradera-Williego opiera się na kombinacji cech klinicznych i analizy genetycznej.1 W ciągu ostatniej dekady wiek diagnostyki znacznie się obniżył, a większość przypadków jest obecnie rozpoznawana w pierwszych miesiącach życia.1

Wczesna diagnoza jest kluczowa dla skutecznego zarządzania zespołem, ponieważ:

  • Umożliwia wdrożenie odpowiednich programów żywieniowych i fizjoterapeutycznych, zapobiegających otyłości i poprawiających kamienie milowe rozwoju motorycznego1
  • Redukuje czas hospitalizacji i czas trwania karmienia przez rurkę1
  • Zapobiega wczesnej otyłości u niemowląt z ZPW1
  • Zwiększa prawdopodobieństwo osiągnięcia przez pacjentów przeciętnej długości życia1

Obecnie ponad 99% przypadków może być zdiagnozowanych za pomocą prostego testu molekularnego – analizy metylacji DNA.1 Testowanie prenatalne nie jest jeszcze rutynowo zalecane, choć teoretycznie można podejrzewać ZPW w przypadkach ograniczonych ruchów płodu i wielowodzia.1

Zalecany nadzór i monitorowanie

Dla osób z zespołem Pradera-Williego zaleca się następujący protokół nadzoru:123

Rodzaj monitorowania Częstotliwość
Monitorowanie postępów rozwojowych i potrzeb edukacyjnych Przy każdej wizycie
Monitorowanie pozycji jąder (wnętrostwo może nawrócić po orchidopeksji) Corocznie
Badanie stężenia hemoglobiny glikowanej i/lub test tolerancji glukozy Corocznie w przypadku otyłości lub od okresu dojrzewania albo przy nagłym, znacznym przyroście masy ciała
Poziomy wolnej tyroksyny i TSH w celu oceny niedoczynności tarczycy Co 6-12 miesięcy, począwszy od niemowlęctwa
Ocena centralnej niewydolności nadnerczy W razie potrzeby, na podstawie objawów podczas choroby lub operacji
Monitorowanie wzrostu, wagi, BMI Co miesiąc w okresie niemowlęcym, co 6 miesięcy w pierwszej dekadzie życia, przynajmniej raz w roku później (częściej, jeśli opiekunowie zauważą szybki przyrost masy ciała)
Ocena zachowań obsesyjno-kompulsywnych Corocznie po 2. roku życia
Ocena psychozy Corocznie u nastolatków i dorosłych (radykalna zmiana zachowania, halucynacje, urojenia lub dezorientacja powinny skłonić do konsultacji psychiatrycznej)
Badanie skóry pod kątem ran i/lub objawów infekcji skórnych Przy każdej wizycie
Badanie okulistyczne pod kątem zeza i/lub wad refrakcji Corocznie
Ocena chrapania, częstego nocnego budzenia się, nowych problemów behawioralnych Corocznie
Badanie kliniczne pod kątem skoliozy Przy każdej wizycie, począwszy od momentu, gdy dziecko może samodzielnie siedzieć
Densytometria kości (badanie DXA) Co 2 lata, począwszy od okresu dojrzewania
Ocena nowych napadów padaczkowych lub monitorowanie istniejących Przy każdej wizycie, według wskazań klinicznych
Ocena stomatologiczna Co najmniej co 6 miesięcy po wyrznięciu zębów lub co 3-4 miesiące w przypadku problemów stomatologicznych
Ocena potrzeb rodziny w zakresie wsparcia socjalnego Przy każdej wizycie

Umieralność i czynniki ryzyka

Pomimo postępów w diagnostyce i leczeniu, zespół Pradera-Williego wciąż wiąże się z podwyższonym ryzykiem przedwczesnej śmierci.12 Według badania przeprowadzonego przez Francuskie Centrum Referencyjne ds. ZPW, w okresie 11 lat (2004-2014) zidentyfikowano 104 zgony, z medianą wieku w momencie śmierci wynoszącą 30 lat (zakres od okresu noworodkowego do 58 lat).1

Główne przyczyny zgonów to:1

Roczna śmiertelność w ZPW waha się między 1% a 4%, a ogólna śmiertelność jest trzykrotnie wyższa niż w ogólnej populacji USA (2,7% vs 0,8%).12

Największy wskaźnik śmiertelności odnotowano wśród pacjentów ze zdiagnozowanym ZPW w wieku 0-2 lat, natomiast najniższy wśród osób w wieku 9-17 lat.1

Systemy nadzoru i rejestry

W celu lepszego zrozumienia epidemiologii zespołu Pradera-Williego oraz poprawy opieki nad pacjentami, na całym świecie tworzone są specjalne rejestry i systemy nadzoru.12

Istniejące rejestry i ich znaczenie

Do ważnych rejestrów i systemów nadzoru należą:

  • Francuskie Centrum Referencyjne ds. ZPW (FRC-PWS) – prowadzi bazę danych pacjentów i monitoruje umieralność1
  • Francuskie Epidemiologiczne Centrum Medycznych Przyczyn Zgonów (CpiDc)1
  • Kanadyjski System Nadzoru Pediatrycznego (CPSP) – prowadził dwuletni nadzór nad ZPW i innymi schorzeniami związanymi z odżywianiem i wzrostem1
  • Globalna Rejestr ZPW – gromadzi dane o pacjentach z całego świata1
  • Australijska baza danych zespołu Pradera-Williego1
  • Sieci rzadkich chorób, w tym Grupa Współpracy ZPW Oddziału Chorób Rzadkich Chińskiego Towarzystwa Pediatrycznego i Grupa Ekspertów Zhejiang ds. ZPW1

Szacunkowy stopień objęcia pacjentów z ZPW przez rejestry krajowe jest jednak ograniczony. W rezultacie, nawet przy zastosowaniu rygorystycznych kryteriów podczas rekrutacji pacjentów do tych rejestrów, nie dostarczają one dokładnego obrazu rzeczywistej liczby zdiagnozowanych przypadków.1

Prognozy i trendy

Najnowsze prognozy epidemiologiczne dla zespołu Pradera-Williego wskazują na pewne trendy:1234

  • W 2023 roku w siedmiu głównych rynkach (USA, Niemcy, Francja, Włochy, Hiszpania, Wielka Brytania i Japonia) odnotowano około 25 000 zdiagnozowanych przypadków ZPW1
  • Stany Zjednoczone utrzymują najwyższą prewalencję i przewiduje się, że utrzymają tę pozycję w okresie prognozy do 2034 roku12
  • Wśród krajów europejskich (EU4 i Wielka Brytania) najwięcej przypadków ZPW w 2023 roku odnotowano w Niemczech, a najmniej w Hiszpanii1
  • W Japonii zaobserwowano, że ZPW występował najczęściej w grupie wiekowej 18-40 lat, stanowiąc ponad 38% wszystkich przypadków w 2023 roku1
  • Wśród specyficznych podtypów genetycznych ZPW w USA w 2023 roku, podtyp mikrodelecji ojcowskiej stanowił największy odsetek, około 70% przypadków, podczas gdy podtyp translokacji był najrzadszy1

Przewiduje się wzrost liczby zdiagnozowanych przypadków, co może wskazywać na potencjalne postępy w rozpoznawaniu choroby i dostępności leczenia.1 Szacuje się, że obecnie około połowa pacjentów jest diagnozowana w pierwszych latach po urodzeniu, jednak wciąż istnieje znaczna luka w identyfikacji rzeczywistych przypadków ZPW na całym świecie.1

Wskaźnik diagnozy wynosi obecnie około 50% w USA i krajach EU4 oraz Wielkiej Brytanii, z tendencją wzrostową od roku bazowego. Przewiduje się, że wskaźnik ten będzie dalej przyspieszał dzięki wprowadzeniu pierwszej terapii, zwiększeniu testów genetycznych oraz wzrostowi świadomości, co prowadzi do zmniejszenia liczby błędnie zdiagnozowanych przypadków.1

Wyzwania w nadzorze epidemiologicznym

Pomimo postępów w diagnostyce i leczeniu zespołu Pradera-Williego, wciąż istnieją znaczące wyzwania w skutecznym nadzorze epidemiologicznym nad tą chorobą.123

Problemy diagnostyczne

Kluczowe wyzwania w diagnozowaniu ZPW obejmują:

  • Znaczna zmienność w wieku diagnozy wśród populacji pacjentów z ZPW, od urodzenia do górnej granicy 20-48 lat w zależności od badanej populacji, z medianą 0,3 roku1
  • Błędna diagnoza lub brak diagnozy, szczególnie w Chinach i innych regionach o ograniczonym dostępie do specjalistycznej opieki zdrowotnej12
  • Diagnoza ZPW u dorosłych często jest pomijana1
  • Diagnostyka prenatalna ZPW pozostaje trudnym celem, który jest przedmiotem obecnie prowadzonych badań1

Diagnostyka prenatalna zwykle ogranicza się do rodzin, w których istnieje znana historia ZPW lub podejrzenie delecji centrum imprintingu lub rearanżacji chromosomowej.1

Potrzeby badawcze

Aby poprawić nadzór epidemiologiczny nad zespołem Pradera-Williego, konieczne są dalsze badania w następujących obszarach:1

  • Monitorowanie umieralności związanej z ZPW
  • Gromadzenie bardziej szczegółowych danych na temat wcześniejszych chorób i okoliczności zgonów
  • Ilościowa ocena wpływu zmian w praktyce klinicznej na przeżywalność pacjentów z ZPW
  • Tworzenie odpowiednich dla rozwoju kryteriów diagnostycznych dla ZPW1
  • Rozwijanie niezawodnych i niedrogich technik analizy molekularnej, niezbędnych do dokładnej i wczesnej diagnozy umożliwiającej rozpoczęcie precyzyjnego leczenia1

Niewiele wiadomo również o ryzyku nowotworów u dorosłych z ZPW ze względu na problemy z diagnozowaniem starszych osób, badania oparte wyłącznie na kwestionariuszach oraz małą liczbę starszych uczestników.1 Badanie przeprowadzone na populacji 706 dzieci i dorosłych z ZPW wykazało, że nowotwory złośliwe są bardzo rzadkie w tej populacji – zdiagnozowano je u mniej niż 1% badanych (7 z 706 osób).12

Znaczenie multidyscyplinarnego podejścia

Złożona genetyka, etiologia, liczne fenotypy i ewoluująca historia naturalna zespołu Pradera-Williego wymaga multidyscyplinarnego podejścia profesjonalnego, rodzicielskiego, społecznego i środowiskowego do zarządzania, z wieloma wyzwaniami mającymi na celu zmniejszenie zachorowalności i śmiertelności oraz poprawę jakości życia.1

Leczenie multidyscyplinarne wykazało zmniejszenie pobytów w szpitalu i zapobieganie wczesnej otyłości.1 Postępowanie w przypadku objawów ZPW zależy od wieku i powinno obejmować wskazówki dotyczące zarządzania konsekwencjami i oczekiwaniami związanymi z zespołem.1

Kompleksowe podejście do leczenia ZPW powinno uwzględniać:1

  • Terapię behawioralną
  • Wczesne zarządzanie dietą
  • Terapię mowy
  • Rutynową profilaktyczną opiekę zdrowotną z ćwiczeniami i lekami
  • Wsparcie psychologiczne i psychospołeczne1
  • Poradnictwo genetyczne w momencie diagnozy, jak również skierowanie do organizacji wsparcia1

Ze względu na niepełnosprawność intelektualną, większość dotkniętych osób wymaga usług wsparcia i jest mniej prawdopodobne, że będą prowadzić w pełni niezależne życie jako dorośli.1

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 10.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 Prader-Willi Syndrome – StatPearls – NCBI Bookshelf
    https://www.ncbi.nlm.nih.gov/books/NBK553161/
    Prader-Willi syndrome has a prevalence of 1 in every 20,000 to 30,000 births. Worldwide, around 400,000 individuals are affected by Prader-Willi syndrome, with 20,000 residing in the United States. It stands as the most prevalent genetic cause of life-threatening obesity. Both females and males are equally affected, with no discernible differences noted among races and ethnicities. […] The prognosis for patients with Prader-Willi syndrome varies, influenced by the timing of diagnosis and the extent of complications. Initiating treatment early and preventing severe obesity increases the likelihood of patients attaining an average lifespan. However, due to intellectual disabilities, most affected individuals require supportive services and are less likely to lead fully independent lives as adults.
  • #1 Prader-Willi syndrome: Clinical features and diagnosis – UpToDate
    https://www.uptodate.com/contents/epidemiology-and-genetics-of-prader-willi-syndrome
    PWS is the most common syndromic form of obesity and affects between 350,000 and 400,000 individuals worldwide. Males and females are affected equally. […] Within the United States, the reported prevalence is between 1:10,000 to 1:30,000. Outside of the United States, reported prevalence rates for PWS range from 1:8000 in rural Sweden to 1:16,000 in Western Japan, 1:16,000 in Australia, and 1:76,500 in Flanders. Within the United Kingdom, the estimated population prevalence is somewhat lower, at approximately 1:45,000. In each of these populations, PWS represents a very small fraction of children with obesity or even severe obesity.
  • #1 Prader-Willi syndrome: Clinical features and diagnosis – UpToDate
    https://www.uptodate.com/contents/prader-willi-syndrome-clinical-features-and-diagnosis
    PWS is the most common syndromic form of obesity and affects between 350,000 and 400,000 individuals worldwide. Males and females are affected equally. […] Although prevalence estimates differ, this is likely due to using different methods for case identification and there is no strong evidence for increased risk in specific countries or gene pools. Within the United States, the reported prevalence is between 1:10,000 to 1:30,000. Outside of the United States, reported prevalence rates for PWS range from 1:8000 in rural Sweden to 1:16,000 in Western Japan, 1:16,000 in Australia, and 1:76,500 in Flanders. Within the United Kingdom, the estimated population prevalence is somewhat lower, at approximately 1:45,000. In each of these populations, PWS represents a very small fraction of children with obesity or even severe obesity.
  • #1 Prader-Willi Syndrome: Background, Pathophysiology, Epidemiology
    https://emedicine.medscape.com/article/947954-overview
    Most cases of Prader-Willi syndrome are sporadic. Burd et al reported a prevalence rate of 1 per 16,062 population. […] Butler reported a prevalence rate of 1 per 25,000 population. […] Prader-Willi syndrome has been reported worldwide. Reported prevalence rates for Prader-Willi syndrome range from 1 per 8000 population in rural Sweden to 1 per 16,000 population in western Japan. […] Despite findings that suggest a prevalence rate of 1 per 52,000 population in the United Kingdom, Whittington et al estimated that the actual prevalence rate is higher and proposed a true prevalence rate of 1 per 45,000 population. […] Complications due to obesity (eg, slipped capital femoral epiphyses, sleep apnea, cor pulmonale, type 2 diabetes mellitus) and behavioral problems are major contributors to morbidity and mortality in individuals with Prader-Willi syndrome.
  • #1 SUN-604 U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims | CoLab
    https://colab.ws/articles/10.1210%2Fjendso%2Fbvaa046.993
    Prader-Willi syndrome (PWS) is a complex developmental genetic disorder associated with hypotonia, poor feeding in neonates, onset of hyperphagia in early childhood, and shorter overall life expectancy. […] The aim of this study was to provide a contemporary estimate of PWS prevalence and annual all-cause mortality in the US using a large administrative medical claims dataset. […] Overall US diagnosed PWS prevalence was 2.7 per 100k persons (or 1 per 37,037), a prevalence of 8,870 patients in the US in 2018. […] The mortality rate was highest among diagnosed PWS patients aged 0-2 years and lowest among those aged 9-17 years and the overall mortality rate was 2.7%. […] Annual PWS mortality is 3 times higher than the overall US population (2.7% vs 0.8%).
  • #1 Prader-Willi Syndrome: Background, Pathophysiology, Epidemiology
    https://emedicine.medscape.com/article/947954-overview
    Assessing a 40-year mortality survey from the Prader-Willi Syndrome Association (USA), Manzardo et al found measurable increases in survival in Prader-Willi syndrome with regard to cardiovascular- and gastrointestinal (GI)-related problems. The investigators said the change was probably the result of „earlier diagnosis and proactive interventions to prevent morbid obesity.” […] Differences in prevalence rates between racial groups have not been consistently reported. […] Prader-Willi syndrome is caused by the loss of the paternal copy in the proximal arm of chromosome 15 in the region of 15p11-13. Differences in prevalence rates between sexes have not been reported. […] Prader-Willi syndrome is a genetic disorder with lifelong implications.
  • #1 Prader-Willi Syndrome (Causes, Symptoms and Treatment)
    https://patient.info/doctor/prader-willi-syndrome-pro
    The estimated prevalence is 1 in 10,000 to 20,000 individuals with a reported range of 1 in 8,000 to 1 in 30,000. […] Most cases of PWS are sporadic with an approximate 1:1 gender ratio. All ethnic groups are represented, but PWS is reported to be disproportionately more in Caucasians. […] Prader-Willi syndrome is the most common known genetic cause of life-threatening obesity in humans.
  • #1 Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02302-z
    Multidisciplinary treatment has been shown to reduce hospital stays and prevent early obesity. […] It was reported that early diagnosis and multidisciplinary care reduce the hospitalization time and duration of tube feeding and prevent early obesity in PWS infants. […] The complex genetics, etiology, multiple phenotypes, and evolving natural history of PWS mean that a multidisciplinary professional, parental, societal, and environmental approach to the management is required with many challenges to reduce morbidity and mortality and improve quality of life.
  • #1 Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02302-z
    Early diagnosis and treatment can significantly improve the prognosis. However, misdiagnosis, missed diagnosis and inappropriate intervention were usually noted. […] The age of diagnosis has dropped significantly over the past decade, with most cases now being diagnosed in the first few months of life. […] The diagnosis of PWS relies on a combination of clinical features and genetic analysis. […] Prenatal diagnosis is not recommended routinely yet, although it can theoretically be suspected in cases of reduced fetal movement and polyhydramnios. […] Reliable and low-cost molecular analysis techniques are imperative for accurate and early diagnosis to start precise treatment. […] Management of the manifestations of PWS depends on age and should include guidance to manage the consequences and expectations of the syndrome.
  • #1 Prader-Willi Syndrome Case Report From Rehabilitation Point Of Vi
    https://www.primescholars.com/articles/praderwilli-syndrome-case-report-from-rehabilitation-point-of-view-100475.html
    Prader-Willi syndrome has been reported worldwide. Reported prevalence rates for Prader-Willi syndrome range from 1 per 8000 population in rural Sweden to 1 per 16,000 population in western Japan. […] Since it is a genetic disorder, PWS has lifelong implications. There is a clear need for an integrated multidisciplinary approach to facilitate early diagnosis and optimize management to improve quality of life, prevent complications, and prolong life expectancy. […] Management of PWS requires multidisciplinary care team that includes combination of behavioral therapy, early diet managements, speech therapy, routine preventive health care with exercises and medications. […] Early diagnosis and intervention allow implementation of reasonable nutrition and physiotherapy programs to prevent obesity and improve motor milestones. […] The most important complications of PWS are related to the cardiovascular and respiratory involvement caused by obesity. These complications are directly responsible for the high incidence of death in children and adults with PWS.
  • #1 Prader–Willi syndrome | European Journal of Human Genetics
    https://www.nature.com/articles/ejhg2008165
    PWS is a common and complex disorder affecting multiple systems. […] Early diagnosis is important to effective long-term management. […] Over 99% can be diagnosed with a simple molecular test, DNA methylation analysis. […] Prader-Willi syndrome (PWS; OMIM 176270) is a relatively common (prevalence 1/15000-1/30000) generally sporadic disorder with a recognizable pattern of dysmorphic features and major neurologic, cognitive, endocrine and behavioral/psychiatric disturbances. […] Management of PWS is focused on anticipatory guidance and addressing the consequences of the syndrome, and is very age-dependent. […] Genetic counselling should also take place at the time of diagnosis, as should referral to support organizations. […] PWS cannot be identified clinically before birth. FISH, DNA polymorphism studies for UPD, and DNA methylation analysis have all been validated for prenatal diagnosis in amniocytes or chorionic villi, and all three are available clinically. Only DNA methylation analysis will identify the imprinting defects.
  • #1 Table 8. [Recommended Surveillance for Individuals with Prader-Willi Syndrome]. – GeneReviews® – NCBI Bookshelf
    https://www.ncbi.nlm.nih.gov/books/NBK1330/table/pws.T.recommended_surveillance_for_indiv/
    Recommended Surveillance for Individuals with Prader-Willi Syndrome. […] Monitor developmental progress educational needs. At each visit. […] Monitor testicular position, as cryptorchidism may recur after orchidopexy. Annually. […] Glycosylated hemoglobin concentration /or glucose tolerance test to assess for diabetes Annually if obese or beginning in adolescence or w/rapid significant weight gain or other symptoms (e.g., polyuria/polydipsia). […] Free thyroxine TSH levels to assess for hypothyroidism Every 6-12 mos beginning in infancy. […] Assess for central adrenal insufficiency As needed based on symptoms during illness surgery. […] Monitor height, weight, BMI. […] Every month in infancy. […] Every 6 mos in 1st decade of life. […] At least annually thereafter. […] More frequently if caregivers identify rapid weight gain.
  • #1 Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1214-2
    In the last 20 years, substantial improvements have been made in the diagnosis, treatment and management of patients with Prader-Willi syndrome (PWS). […] Our study assessed the causes of death among French patients with PWS over the first 11 years of experience of the nationwide French Reference Center for PWS (FRC-PWS). […] The French Epidemiological Centre for the Medical Causes of Death (CpiDc) Registry and the FRC-PWS database were used as sources of mortality information at national level between 2004 and 2014. […] The current study aimed to describe the causes of death among patients with PWS over the first 11 years of the Reference Center’s experience, from 2004 to 2014. […] In our study, we identified 104 deaths over 11 years, which makes this one of the largest recently reported cohorts.
  • #1 Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1214-2
    The median age at death was 30 years, ranging from neonatal to 58 years. […] Respiratory causes accounted for more than 50% of the deaths in patients with PWS. […] Among adults, most deaths were caused by respiratory failure, while respiratory infections were the primary cause of death in children. […] The causes of death differed between children and adults (p=0.017). […] The primary causes of death among children in the first year of life were: respiratory infection (n=2), cardiac failure (n=1), cardiac tamponade (n=1), pneumococcal meningitis (n=1), and sudden death (n=2). […] In summary, patients with PWS die prematurely. […] PWS is a life-threatening condition with an excessive risk of mortality compared to the general population. […] Further research is needed to monitor the mortality, gather more detailed data on antecedents and contexts of death and quantify the impact of changes in clinical practice on the survival of patients with PWS.
  • #1 Prader-Willi Syndrome Market Size & Share 2035
    https://www.imarcgroup.com/prader-willi-syndrome-market
    The prevalence of Prader-Willi syndrome is one in every 20,000 to 30,000 births. […] Prader-Willi syndrome affects around 400,000 people worldwide, 20,000 of whom live in the United States. […] It remains the most common hereditary cause of life-threatening obesity. […] The reported prevalence rates for Prader-Willi syndrome range from one per 8,000 people in rural Sweden to one per 16,000 people in western Japan. […] The annual mortality rate of PWS ranges between 1% and 4%. […] IMARC Group’s new report provides an exhaustive analysis of the Prader-Willi syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.
  • #1 97 Active Surveillance of Early-Onset Eating Disorders, Prader-Willi Syndrome and Vitamin D Deficiency Rickets | Pediatric Research
    https://www.nature.com/articles/pr2005349
    Objective: CPSP undertook 2-year surveillance of three nutrition and growth-related conditions: early-onset eating disorders (EOED), Prader-Willi syndrome (PWS) and vitamin D deficiency rickets (VDDR). Canadian incidence estimates were needed to test hypotheses that EOED cases are being missed because current diagnostic criteria do not apply to children aged 512 years, that early identification of PWS and related-obesity as well as increasing cases of VDDR are public health issues. […] The PWS study identified 35 genetically confirmed cases, diagnosed at a mean age of three years. Of the 28 with available data, 25 had infantile feeding problems and 43% had gained excess weight between 16 years of age. […] The findings indicate a need for creating developmentally appropriate EOED diagnostic criteria, for identifying PWS early and for heightened awareness of rickets prevention among health care providers.
  • #1 Malignancies in Prader-Willi Syndrome: What New Research Reveals
    https://www.fpwr.org/blog/malignancies-in-prader-willi-syndrome-what-new-research-reveals
    Many of the symptoms of Prader-Willi syndrome (PWS) are well known, including problems with the hypothalamus, low muscle tone, hyperphagia, behavioral issues, and the risk of obesity and related complications. […] Not much is known about the risk of cancer in adults with PWS due to issues around the diagnosis of older individuals, questionnaire-only-based studies, and low numbers of older participants. […] These researchers found that in this population of 706 children and adults with PWS, less than one percent had been diagnosed with a malignancy (7 out of 706 in total, which included 4 adult males and three adult females). […] Overall, these researchers found that cancer diagnosis was very rare among this population, with only 7 out of 706 (0.99%) children and adults with PWS who were found to have a malignancy.
  • #1 Prader-Willi syndrome Care of adults in general practice
    https://www.racgp.org.au/afp/2013/january-february/prader-willi-syndrome
    Prader-Willi syndrome is a severely disabling genetic condition. […] Information on the prevalence and mortality of people with PWS is limited. Mortality is high, approximately 3% per annum, and the average age of death was 33.2 years in a study of adults. […] The number of people in Australia with known PWS by year of birth, based on data from the Australian Prader-Willi syndrome database, is presented in Figure 2. At least 261 cases have been genetically confirmed and are seen in hospital-based PWS clinics. One in 17 000 would be a conservative estimate of the birth incidence in the past two decades. […] Information on adults diagnosed with PWS is scarce and the total number of adult patients seen by specialists or general practitioners is currently unknown. Diagnosis of adults may be based on clinical characteristics only, which are not always confirmed genetically. […] A diagnosis of PWS in adults is often missed. In addition, diagnosis of PWS on only clinical characteristics is uncertain.
  • #1 Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02302-z
    Prader-Willi syndrome (PWS) is a complex and multisystem neurobehavioral disease, which is caused by the lack of expression of paternally inherited imprinted genes on chromosome15q11.2-q13.1. […] Its estimated incidence ranges from 1 in 10,000 to 1 in 30,000, with equal number of males and females affected. […] Although some rare disease networks, including PWS Cooperation Group of Rare Diseases Branch of Chinese Pediatric Society, Zhejiang Expert Group for PWS, were established recently, misdiagnosis, missed diagnosis and inappropriate intervention were usually noted in China. Therefore, there is an urgent need for an integrated multidisciplinary approach to facilitate early diagnosis and optimize management to improve quality of life, prevent complications, and prolong life expectancy.
  • #1 Prader-Willi Syndrome – Epidemiology Forecast – 2034
    https://www.researchandmarkets.com/reports/5525575/prader-willi-syndrome-epidemiology-forecast?srsltid=AfmBOoqtEMlPJcBzhDRhuk2I-jzGjQb5amCgY5dqPd7-B8CVxcHsPPHk
    The estimated coverage of PWS patients in country-specific registries is limited. As a result, even when strict criteria are applied during patient recruitment for these registries, they do not provide an accurate representation of the actual diagnosed cases. […] Among the 7MM, the US accounted for the highest prevalent cases of PWS in 2023, with around 22,600 cases; these cases are expected to increase during the forecast period. […] In 2023, the total number of prevalent cases of PWS in EU4 and the UK was highest in Germany, while the lowest number of cases was in Spain. […] According to the estimates, in Japan, it is observed that PWS was most prevalent in the 18-40 years age group, accounting for over 38% of total cases in 2023. […] In 2023, among genetic subtype-specific cases of PWS in the US, the paternal microdeletion subtype accounted for the highest proportion, approximately 70% of cases, while the translocation subtype was the least common.
  • #1 Comprehensive Epidemiology Forecast Reveals Significant
    https://www.globenewswire.com/news-release/2024/12/02/2989523/28124/en/Comprehensive-Epidemiology-Forecast-Reveals-Significant-Insights-into-Prader-Willi-Syndrome-Through-2034.html
    A recent epidemiology forecast provides an extensive review of Prader-Willi Syndrome (PWS), projecting the evolution of the disease through 2034. […] The study spans seven major markets including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, offering a comprehensive overview of the patient population dynamics for PWS. During the forecast period, the United States is expected to maintain the highest prevalence, whereas trends in Europe and Japan highlight varying age-group and genetic subtype specifics in relation to PWS. […] The report emphasizes the importance of early diagnosis and intervention, highlighting the challenges faced by patients and medical professionals in the identification and management of PWS. A focus is placed on the emerging diagnostic rates, which are anticipated to improve due to increased awareness, the availability of genetic testing, and the introduction of new therapies.
  • #1 Prader-Willi Syndrome – Epidemiology Forecast – 2034
    https://www.researchandmarkets.com/reports/5525575/prader-willi-syndrome-epidemiology-forecast?srsltid=AfmBOoqtEMlPJcBzhDRhuk2I-jzGjQb5amCgY5dqPd7-B8CVxcHsPPHk
    In 2023, in the 7MM there were around 25,000 diagnosed prevalent cases of PWS. […] Even though roughly half of the patients are diagnosed in the initial years after birth, there is still a significant gap in the identification of actual diagnosed PWS cases worldwide. This gap can be depicted through a 50% diagnosis rate in the US and EU4+ UK, which is already witnessing a YoY growth from the base year. Moreover, this rate is further expected to accelerate due to the launch of its first therapy, increase in genetic testing, and increase in awareness leading to fewer misdiagnosed cases. […] The PWS epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of PWS, total diagnosed prevalent cases of PWS, age-specific cases of PWS, and PWS cases by Genetic Subtype in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
  • #1 Comprehensive Epidemiology Forecast Reveals Significant
    https://www.globenewswire.com/news-release/2024/12/02/2989523/28124/en/Comprehensive-Epidemiology-Forecast-Reveals-Significant-Insights-into-Prader-Willi-Syndrome-Through-2034.html
    An in-depth analysis of historical and forecasted epidemiology divides the patient population by total prevalent and diagnosed cases, age-specific incidence, and genetic subtype distribution. A projected growth in diagnosed cases points to potential advances in disease recognition and treatment accessibility. […] By forecasting an eleven-year horizon across critical demographics, this report offers insights into epidemiology segmentation and the current state of diagnostic practices. Not only does it shed light on the disease risks and burdens but also encapsulates perspectives on the unmet needs and growth opportunities within PWS patient care. […] This comprehensive forecast serves as a keystone for informed decision-making and strategic planning in healthcare pertaining to Prader-Willi Syndrome. It leverages data to provide an outlook on patient populations, offering clarity on the future state of PWS within diverse geographic markets and emphasizing the ongoing evolution in diagnostics and patient management strategies.
  • #1 A Review of Prader–Willi Syndrome
    https://www.mdpi.com/2673-396X/3/2/27
    Prader-Willi Syndrome (PWS) is a rare complex genetic disorder due to the loss of expression of paternally derived genes in the PWS critical region on chromosome 15q11-q13. […] The incidence of the disease is estimated to be between 1/10,000 and 1/45,000 live births, and the average life expectancy is 29.5 years. […] Currently, PWS is the most commonly known cause of syndromic obesity and the most common cause of obesity-related mortality. […] The diagnosis of PWS is complicated by its considerable range of phenotypic variance as well as the heterogeneity of genetic mechanism underlying the disease, thus centering it as the subject of considerable research interest. […] There is considerable variability in age at diagnosis among the PWS patient population, spanning from birth to an upper bound of 20 to 48 years depending on the sample’s population, with a median of 0.3 years.
  • #1 A Review of Prader–Willi Syndrome
    https://www.mdpi.com/2673-396X/3/2/27
    Earlier diagnosis and treatment are associated with better outcomes in several measurements of PWS morbidity and is a central aim of PWS research. […] Once adequate clinical suspicion for PWS exists, patients are referred for the preferred screening test, methylation analysis, followed by confirmatory testing to detect the subtype that has classically been karyotyping with FISH to reveal deletions and rearrangements on chromosome 15. […] Prenatal testing is usually limited to families in which there is a known history of PWS or otherwise suspicion for an imprinting center deletion or chromosomal rearrangement. […] The reliable prenatal diagnosis of PWS has remained an elusive goal that is the focus of current research efforts.
  • #1 Current Perspectives Of Prader Willi Syndrome: A Multisystem Approach » Article
    https://journals.stmjournals.com/article/article=2024/view=165347/
    Prader-Willi syndrome (PWS) is a genetic disorder with multisystem involvement, caused by the lack of expression of genes on the paternally inherited chromosome 15q11.2-q13 region from paternal 15q11-q13 deletions (about 60%) or maternal uniparental disomy 15 or both. […] Specific diagnostic criteria for PWS are both the methylation analysis and the oligo-SNP combination array (OSA). Early diagnosis is needed for the effective management. […] Currently, there were no approved therapy for the management of hyperphagia in PWS. […] Nutritional counselling for long term weight management is necessary to prevent the inappropriate weight gain, which begin at the age between 1-3 years. […] Psychological and psychosocial considerations are essential for PWS.
  • #2 Prader-Willi syndrome: Clinical features and diagnosis – UpToDate
    https://www.uptodate.com/contents/epidemiology-and-genetics-of-prader-willi-syndrome
    PWS is the most common syndromic form of obesity and affects between 350,000 and 400,000 individuals worldwide. Males and females are affected equally. […] Within the United States, the reported prevalence is between 1:10,000 to 1:30,000. Outside of the United States, reported prevalence rates for PWS range from 1:8000 in rural Sweden to 1:16,000 in Western Japan, 1:16,000 in Australia, and 1:76,500 in Flanders. Within the United Kingdom, the estimated population prevalence is somewhat lower, at approximately 1:45,000. In each of these populations, PWS represents a very small fraction of children with obesity or even severe obesity.
  • #2 Prader-Willi Syndrome Market Size & Share 2035
    https://www.imarcgroup.com/prader-willi-syndrome-market
    The prevalence of Prader-Willi syndrome is one in every 20,000 to 30,000 births. […] Prader-Willi syndrome affects around 400,000 people worldwide, 20,000 of whom live in the United States. […] It remains the most common hereditary cause of life-threatening obesity. […] The reported prevalence rates for Prader-Willi syndrome range from one per 8,000 people in rural Sweden to one per 16,000 people in western Japan. […] The annual mortality rate of PWS ranges between 1% and 4%. […] IMARC Group’s new report provides an exhaustive analysis of the Prader-Willi syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.
  • #2 Prader-Willi Syndrome (Causes, Symptoms and Treatment)
    https://patient.info/doctor/prader-willi-syndrome-pro
    The estimated prevalence is 1 in 10,000 to 20,000 individuals with a reported range of 1 in 8,000 to 1 in 30,000. […] Most cases of PWS are sporadic with an approximate 1:1 gender ratio. All ethnic groups are represented, but PWS is reported to be disproportionately more in Caucasians. […] Prader-Willi syndrome is the most common known genetic cause of life-threatening obesity in humans.
  • #2 Prader-Willi syndrome: Clinical features and diagnosis – UpToDate
    https://www.uptodate.com/contents/prader-willi-syndrome-clinical-features-and-diagnosis
    PWS is the most common syndromic form of obesity and affects between 350,000 and 400,000 individuals worldwide. Males and females are affected equally. […] Although prevalence estimates differ, this is likely due to using different methods for case identification and there is no strong evidence for increased risk in specific countries or gene pools. Within the United States, the reported prevalence is between 1:10,000 to 1:30,000. Outside of the United States, reported prevalence rates for PWS range from 1:8000 in rural Sweden to 1:16,000 in Western Japan, 1:16,000 in Australia, and 1:76,500 in Flanders. Within the United Kingdom, the estimated population prevalence is somewhat lower, at approximately 1:45,000. In each of these populations, PWS represents a very small fraction of children with obesity or even severe obesity.
  • #2 Orphanet: Prader-Willi syndrome
    https://www.orpha.net/en/disease/detail/739
    Prevalence at birth is estimated at 1/15,000-30,000 worldwide. […] Most cases are sporadic; however, in rare cases dominant transmission may occur with 50% risk where the father carries the imprinting defect. […] Early diagnosis, early multidisciplinary care and GH treatment have greatly improved the quality of life of affected children.
  • #2 Table 8. [Recommended Surveillance for Individuals with Prader-Willi Syndrome]. – GeneReviews® – NCBI Bookshelf
    https://www.ncbi.nlm.nih.gov/books/NBK1330/table/pws.T.recommended_surveillance_for_indiv/
    Assess for presence of behavioral findings obsessive-compulsive features w/family or caregivers. Annually after age 2 yrs. […] Assess for psychosis. […] Evidence of radical behavior change, hallucinations, delusions, or disorientation should prompt psychiatry eval. Annually in adolescents adults. […] Skin exam for sores /or signs/symptoms of cutaneous infection At each visit. […] Ophthalmologic exam to assess for strabismus /or refractive errors Annually. […] Assess for snoring, frequent nocturnal awakening, new behavioral issues w/family or caregivers. Annually. […] Clinical exam for scoliosis At each visit beginning when child can sit independently. […] Bone densitometry by DXA scan Every 2 yrs beginning in adolescence. […] Assess for new seizures or monitor those w/seizures as clinically indicated. At each visit.
  • #2 Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1214-2
    The median age at death was 30 years, ranging from neonatal to 58 years. […] Respiratory causes accounted for more than 50% of the deaths in patients with PWS. […] Among adults, most deaths were caused by respiratory failure, while respiratory infections were the primary cause of death in children. […] The causes of death differed between children and adults (p=0.017). […] The primary causes of death among children in the first year of life were: respiratory infection (n=2), cardiac failure (n=1), cardiac tamponade (n=1), pneumococcal meningitis (n=1), and sudden death (n=2). […] In summary, patients with PWS die prematurely. […] PWS is a life-threatening condition with an excessive risk of mortality compared to the general population. […] Further research is needed to monitor the mortality, gather more detailed data on antecedents and contexts of death and quantify the impact of changes in clinical practice on the survival of patients with PWS.
  • #2 SUN-604 U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims | CoLab
    https://colab.ws/articles/10.1210%2Fjendso%2Fbvaa046.993
    Prader-Willi syndrome (PWS) is a complex developmental genetic disorder associated with hypotonia, poor feeding in neonates, onset of hyperphagia in early childhood, and shorter overall life expectancy. […] The aim of this study was to provide a contemporary estimate of PWS prevalence and annual all-cause mortality in the US using a large administrative medical claims dataset. […] Overall US diagnosed PWS prevalence was 2.7 per 100k persons (or 1 per 37,037), a prevalence of 8,870 patients in the US in 2018. […] The mortality rate was highest among diagnosed PWS patients aged 0-2 years and lowest among those aged 9-17 years and the overall mortality rate was 2.7%. […] Annual PWS mortality is 3 times higher than the overall US population (2.7% vs 0.8%).
  • #2 Prader-Willi syndrome – CPSP
    https://cpsp.cps.ca/surveillance/study-etude/prader-willi-syndrome
    Human growth hormone therapy in Prader-Willi syndrome […] Helping to prevent obesity and complications in children with Prader-Willi syndrome […] Surveillance of rare genetic disorders: No longer orphan diseases […] Canadian incidence of Prader-Willi syndrome […] Active surveillance of early-onset eating disorders, vitamin D deficiency rickets, and Prader-Willi syndrome […] Surveillance helping patients with orphan genetic disorders.
  • #2 Comprehensive Epidemiology Forecast Reveals Significant
    https://www.globenewswire.com/news-release/2024/12/02/2989523/28124/en/Comprehensive-Epidemiology-Forecast-Reveals-Significant-Insights-into-Prader-Willi-Syndrome-Through-2034.html
    An in-depth analysis of historical and forecasted epidemiology divides the patient population by total prevalent and diagnosed cases, age-specific incidence, and genetic subtype distribution. A projected growth in diagnosed cases points to potential advances in disease recognition and treatment accessibility. […] By forecasting an eleven-year horizon across critical demographics, this report offers insights into epidemiology segmentation and the current state of diagnostic practices. Not only does it shed light on the disease risks and burdens but also encapsulates perspectives on the unmet needs and growth opportunities within PWS patient care. […] This comprehensive forecast serves as a keystone for informed decision-making and strategic planning in healthcare pertaining to Prader-Willi Syndrome. It leverages data to provide an outlook on patient populations, offering clarity on the future state of PWS within diverse geographic markets and emphasizing the ongoing evolution in diagnostics and patient management strategies.
  • #2 Prader-Willi Syndrome Treatment Landscape Poised for Transformative Growth by 2034, Reports DelveInsight
    https://www.einpresswire.com/article/773503449/prader-willi-syndrome-treatment-landscape-poised-for-transformative-growth-by-2034-reports-delveinsight
    Some of the key insights of Prader-Willi Syndrome Market Report: Among the 7MM, the US accounted for the highest prevalent cases of Prader-Willi syndrome (PWS) in 2023, with approximately 22,600 cases, and these cases are expected to increase during the forecast period. […] The Prader-Willi Syndrome market report proffers epidemiological analysis for the study period 20202034 in the 7MM segmented into: Total Prevalent Cases of Prader-Willi Syndrome in the 7MM Diagnosed Prevalent Cases of Prader-Willi Syndrome in the 7MM Mutation-specific Diagnosed Prevalent Cases of Prader-Willi Syndrome in the 7MM Treated Cases of Prader-Willi Syndrome in the 7MM. […] The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.
  • #2 Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China | Orphanet Journal of Rare Diseases | Full Text
    https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02302-z
    Early diagnosis and treatment can significantly improve the prognosis. However, misdiagnosis, missed diagnosis and inappropriate intervention were usually noted. […] The age of diagnosis has dropped significantly over the past decade, with most cases now being diagnosed in the first few months of life. […] The diagnosis of PWS relies on a combination of clinical features and genetic analysis. […] Prenatal diagnosis is not recommended routinely yet, although it can theoretically be suspected in cases of reduced fetal movement and polyhydramnios. […] Reliable and low-cost molecular analysis techniques are imperative for accurate and early diagnosis to start precise treatment. […] Management of the manifestations of PWS depends on age and should include guidance to manage the consequences and expectations of the syndrome.
  • #2 Malignancies in Prader-Willi Syndrome: What New Research Reveals
    https://www.fpwr.org/blog/malignancies-in-prader-willi-syndrome-what-new-research-reveals
    Overall, the data from these studies and the Global PWS Registry are reassuring and do not suggest an increased cancer risk in persons with PWS compared to the general population. However, it is known that there is an increased risk of cancer associated with obesity, so the authors do recommend participation in national screening programs for breast and colon cancer in all adults with PWS.
  • #3 Prader-Willi syndrome: MedlinePlus GeneticsLock
    https://medlineplus.gov/genetics/condition/prader-willi-syndrome/
    Prader-Willi syndrome affects an estimated 1 in 10,000 to 30,000 people worldwide. […] Most cases of Prader-Willi syndrome are not inherited, particularly those caused by a deletion in the paternal chromosome 15 or by maternal uniparental disomy. These genetic changes occur as random events during the formation of reproductive cells (eggs and sperm) or in early embryonic development. Affected people typically have no history of the disorder in their family.
  • #3 Prader-Willi Syndrome – StatPearls – NCBI Bookshelf
    https://www.ncbi.nlm.nih.gov/books/NBK553161/
    Prader-Willi syndrome has a prevalence of 1 in every 20,000 to 30,000 births. Worldwide, around 400,000 individuals are affected by Prader-Willi syndrome, with 20,000 residing in the United States. It stands as the most prevalent genetic cause of life-threatening obesity. Both females and males are equally affected, with no discernible differences noted among races and ethnicities. […] The prognosis for patients with Prader-Willi syndrome varies, influenced by the timing of diagnosis and the extent of complications. Initiating treatment early and preventing severe obesity increases the likelihood of patients attaining an average lifespan. However, due to intellectual disabilities, most affected individuals require supportive services and are less likely to lead fully independent lives as adults.
  • #3 Prader-Willi Syndrome – EyeWiki
    https://eyewiki.org/Prader-Willi_Syndrome
    Prader-Willi syndrome affects approximately 1 in 25,000 live births, with males and females affected equally. […] Currently, Prader-Willi syndrome affects about 350,000 – 400,000 individuals worldwide. Prevalence estimates differ among studies, however it is likely due to different testing methods rather than an increased risk in specific populations or countries. […] The risk of recurrence in siblings is very low unless a deletion affecting the imprinting center is present, accounting for less than 1 percent of cases.
  • #3 Table 8. [Recommended Surveillance for Individuals with Prader-Willi Syndrome]. – GeneReviews® – NCBI Bookshelf
    https://www.ncbi.nlm.nih.gov/books/NBK1330/table/pws.T.recommended_surveillance_for_indiv/
    Dental eval At least every 6 mos after teeth erupt or every 3-4 mos if dental issues are present. […] Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). At each visit.
  • #3 Prader-Willi Syndrome – Epidemiology Forecast – 2034
    https://www.researchandmarkets.com/reports/5525575/prader-willi-syndrome-epidemiology-forecast?srsltid=AfmBOoqtEMlPJcBzhDRhuk2I-jzGjQb5amCgY5dqPd7-B8CVxcHsPPHk
    In 2023, in the 7MM there were around 25,000 diagnosed prevalent cases of PWS. […] Even though roughly half of the patients are diagnosed in the initial years after birth, there is still a significant gap in the identification of actual diagnosed PWS cases worldwide. This gap can be depicted through a 50% diagnosis rate in the US and EU4+ UK, which is already witnessing a YoY growth from the base year. Moreover, this rate is further expected to accelerate due to the launch of its first therapy, increase in genetic testing, and increase in awareness leading to fewer misdiagnosed cases. […] The PWS epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of PWS, total diagnosed prevalent cases of PWS, age-specific cases of PWS, and PWS cases by Genetic Subtype in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
  • #3 Prader-Willi syndrome Care of adults in general practice
    https://www.racgp.org.au/afp/2013/january-february/prader-willi-syndrome
    Prader-Willi syndrome is a severely disabling genetic condition. […] Information on the prevalence and mortality of people with PWS is limited. Mortality is high, approximately 3% per annum, and the average age of death was 33.2 years in a study of adults. […] The number of people in Australia with known PWS by year of birth, based on data from the Australian Prader-Willi syndrome database, is presented in Figure 2. At least 261 cases have been genetically confirmed and are seen in hospital-based PWS clinics. One in 17 000 would be a conservative estimate of the birth incidence in the past two decades. […] Information on adults diagnosed with PWS is scarce and the total number of adult patients seen by specialists or general practitioners is currently unknown. Diagnosis of adults may be based on clinical characteristics only, which are not always confirmed genetically. […] A diagnosis of PWS in adults is often missed. In addition, diagnosis of PWS on only clinical characteristics is uncertain.
  • #4 Prader-Willi Syndrome and Angelman Syndrome | Concise Medical Knowledge
    https://www.lecturio.com/concepts/prader-willi-syndrome-and-angelman-syndrome/
    Prader-Willi syndrome (PWS) prevalence is about 1 in 15,000 to 1 in 30,000 live births in the United States, and affects between 350,000 and 400,000 individuals worldwide. […] Both sexes are affected equally. […] Prevalence of Angelman syndrome (AS) is about 1 in 10,000 to 1 in 20,000 live births. […] No gender or racial predominance. […] Vast majority of cases are sporadic rather than familial.
  • #4 Prader-Willi Syndrome – Epidemiology Forecast – 2034
    https://www.researchandmarkets.com/reports/5525575/prader-willi-syndrome-epidemiology-forecast?srsltid=AfmBOoqtEMlPJcBzhDRhuk2I-jzGjQb5amCgY5dqPd7-B8CVxcHsPPHk
    The estimated coverage of PWS patients in country-specific registries is limited. As a result, even when strict criteria are applied during patient recruitment for these registries, they do not provide an accurate representation of the actual diagnosed cases. […] Among the 7MM, the US accounted for the highest prevalent cases of PWS in 2023, with around 22,600 cases; these cases are expected to increase during the forecast period. […] In 2023, the total number of prevalent cases of PWS in EU4 and the UK was highest in Germany, while the lowest number of cases was in Spain. […] According to the estimates, in Japan, it is observed that PWS was most prevalent in the 18-40 years age group, accounting for over 38% of total cases in 2023. […] In 2023, among genetic subtype-specific cases of PWS in the US, the paternal microdeletion subtype accounted for the highest proportion, approximately 70% of cases, while the translocation subtype was the least common.

Zobacz więcej

niewydolność oddechowa choroba rzadka skolioza wielowodzie translokacja metylacja DNA zespół Pradera-Williego wada refrakcji napad padaczkowy niewydolność serca densytometria kości analiza genetyczna zapalenie opon mózgowych hemoglobina glikowana orchidopeksja nowotwór złośliwy zez infekcja dróg oddechowych diagnostyka prenatalna problemy behawioralne centralna niewydolność nadnerczy tamponada serca wolna tyroksyna wnętrostwo niepełnosprawność intelektualna niedoczynność tarczycy test tolerancji glukozy specjalistyczna opieka zdrowotna